Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 603 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Antidepressant Medication Clear all
Completed Phase 2 Interventional Results available

Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder

NCT01469377
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, Cariprazine
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
819 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
39
States / cities
Garden Grove, California • National City, California • Oceanside, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Oct 23, 2026, 1:15 AM EDT
Completed Not applicable Interventional Results available

Treating Caregiver Depression to Improve Childhood Asthma: Impact and Mediators

NCT02809677
View directory record Official record
Conditions
Asthma, Major Depressive Disorder
Interventions
Non-Interventional
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
7 Years to 70 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Oct 23, 2026, 1:15 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Effects of Antidepressant Therapy on Brain Dopamine Transporter Activity in People With Major Depression

NCT00655057
View directory record Official record
Conditions
Depression
Interventions
S-citalopram, Cognitive behavioral therapy (CBT), TRODAT-1 single photon emission computed tomographic (SPECT) imaging
Drug · Behavioral · Procedure
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 16, 2020 · Synced Oct 23, 2026, 1:15 AM EDT
Completed Phase 3 Interventional Results available

Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy

NCT01942785
View directory record Official record
Conditions
Major Depressive Disorder, Irritability
Interventions
Brexpiprazole
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
15
States / cities
Tucson, Arizona • Glendale, California • Oakland, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2016 · Synced Oct 23, 2026, 1:15 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features

NCT00637494
View directory record Official record
Conditions
Psychotic Depression, Severe Major Depression With Psychotic Features, Psychosis
Interventions
mifepristone, placebo
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
22 Years and older
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
42
States / cities
Little Rock, Arkansas • Anaheim, California • Downey, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 23, 2026, 1:15 AM EDT
Active, not recruiting Not applicable Interventional

Low Field Magnetic Stimulation: Imaging Biomarkers in Geriatric Bipolar Depression

NCT03484494
View directory record Official record
Conditions
Bipolar Disorder, Bipolar Depression, Bipolar I Disorder, Bipolar II Disorder
Interventions
Low Field Magnetic Stimulation
Device
Lead sponsor
Mclean Hospital
Other
Eligibility
50 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 23, 2026, 1:15 AM EDT
Completed Phase 2Phase 3 Interventional

Treatment of SSRI-Resistant Depression In Adolescents (TORDIA)

NCT00018902
View directory record Official record
Conditions
Depression
Interventions
Fluoxetine, Venlafaxine, Cognitive Behavioral Therapy (CBT), Citalopram
Drug · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
12 Years to 18 Years
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
6
States / cities
Los Angeles, California • Portland, Oregon • Pittsburgh, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2014 · Synced Oct 23, 2026, 1:15 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Clinical Trial of Pramipexole in Bipolar Depression

NCT00025792
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Pramipexole
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 23, 2026, 1:15 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder (MDD)

NCT01157078
View directory record Official record
Conditions
Major Depressive Disorder, Depression
Interventions
TC-5214, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
37
States / cities
Tuscaloosa, Alabama • Tucson, Arizona • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2014 · Synced Oct 23, 2026, 1:15 AM EDT
Withdrawn Phase 2 Interventional

Neuroimaging Predictors of Antidepressant Treatment Outcome

NCT02000726
View directory record Official record
Conditions
Depression
Interventions
Placebo, Citalopram, Fast acting antidepressant-like treatment. administered i.v. during the fMRI scanning session
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 21, 2016 · Synced Oct 23, 2026, 1:15 AM EDT
Recruiting Phase 2 Interventional

5-HTP and Creatine for Depression R33 Phase

NCT05895747
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Low Dose 5-hydroxytryptophan, High Dose 5-hydroxytryptophan, Low Dose Creatine Monohydrate, High Dose Creatine Monohydrate, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 65 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 23, 2026, 1:15 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD)

NCT05518149
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Aticaprant
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
871 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
87
States / cities
Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 70 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 23, 2026, 1:15 AM EDT
Completed Phase 4 Interventional Results available

Combination Treatment Study for Memory Impairment and Depression

NCT01658228
View directory record Official record
Conditions
Depression, Mild Cognitive Impairment
Interventions
Donepezil, Placebo, Citalopram, Venlafaxine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
55 Years to 95 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
New York, New York • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 17, 2017 · Synced Oct 23, 2026, 1:15 AM EDT
Completed Phase 2 Interventional Results available

BTRX-246040 Administered Once Daily to Patients With Major Depressive Disorder

NCT03193398
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
BTRX-246040 oral capsule(s), Placebo oral capsule(s)
Drug
Lead sponsor
BlackThorn Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
8
States / cities
Cerritos, California • Garden Grove, California • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 23, 2026, 1:15 AM EDT
Completed Not applicable Interventional Results available

Biomarkers in Repetitive Transcranial Magnetic Stimulation (rTMS) for Adolescent Depression

NCT03363919
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
NeuroStar TMS Therapy® System, NeuroStar XPLOR®
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
12 Years to 18 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Oct 23, 2026, 1:15 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Dynamic Measures of Neurochemistry in Mood Disorders

NCT00178828
View directory record Official record
Conditions
Depression
Interventions
sertraline, bupropion
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 23, 2026, 1:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Behavioral Effects of Drugs (Inpatient): 40 [Methamphetamine, Methylphenidate, Duloxetine]

NCT04178993
View directory record Official record
Conditions
Methamphetamine Use Disorder
Interventions
Methamphetamine, Methylphenidate, Placebo oral capsule, Duloxetine
Drug
Lead sponsor
Craig Rush
Other
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
2
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Oct 23, 2026, 1:15 AM EDT
Completed Phase 4 Interventional Results available

A Study Comparing Duloxetine to Other Antidepressants in the Treatment of Severe Depression

NCT00666757
View directory record Official record
Conditions
Depression
Interventions
duloxetine, fluoxetine, citalopram, paroxetine, sertraline
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
61
States / cities
Carson, California • Irvine, California • San Diego, California + 58 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2010 · Synced Oct 23, 2026, 1:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of Genetic Differences in People With Depression

NCT00229463
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2016 · Synced Oct 23, 2026, 1:15 AM EDT
Completed Phase 2 Interventional

A Study of Intermittent Doses of CERC-301 in MDD

NCT02459236
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
CERC-301, Placebo
Drug
Lead sponsor
Avalo Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
13
States / cities
Newport Beach, California • Alpharetta, Georgia • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2017 · Synced Oct 23, 2026, 1:15 AM EDT
Completed Phase 2 Interventional

AZD6765 for Treatment Resistant Depression

NCT00491686
View directory record Official record
Conditions
Depression
Interventions
AZD6765
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
21 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
5
States / cities
Glendale, California • Hartford, Connecticut • New Haven, Connecticut + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2011 · Synced Oct 23, 2026, 1:15 AM EDT
Completed Phase 2 Interventional Results available

5-HTP and Creatine for Depression

NCT04395183
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
5-Hydroxytryptophan 100 MG, Creatine monohydrate, placebo matched to 5-HTP, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
25 Years to 40 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 23, 2024 · Synced Oct 23, 2026, 1:15 AM EDT
Recruiting Phase 2 Interventional

Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression

NCT06591091
View directory record Official record
Conditions
Depression
Interventions
Clemastine Fumarate, Placebo
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
60 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 23, 2026, 1:15 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Magnetic Brain Stimulation for the Treatment of Adult Depression

NCT00149838
View directory record Official record
Conditions
Depression
Interventions
Prefrontal rTMS, Antidepressant Regimen, Sham Stimulation
Procedure · Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
21 Years to 70 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
4
States / cities
Atlanta, Georgia • New York, New York • Charleston, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2018 · Synced Oct 23, 2026, 1:15 AM EDT